NCT06734130View on ClinicalTrials.gov

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
DRUG

Luteinizing Hormone-Releasing Hormone (LHRH) analog

The choice of the standard of care LHRH analog will be at the discretion of the treating physician.

DRUG

Androgen Receptor Signal Inhibitor (ARSI)

The choice of the standard of care ARSI will be at the discretion of the treating physician.

DRUG

Docetaxel

Docetaxel will be given by IV infusion at 75mg/m2 once every 3 weeks.

Trial Locations (1)

33612

RECRUITING

Moffitt Caner Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER